Search Results
Your search for ,led matches 5952 pages
Showing 1101 - 1150Olutasidenib for Relapsed or Refractory Acute Myeloid Leukemia With a Susceptible IDH1 Mutation
On December 1, 2022, the IDH1 inhibitor olutasidenib was approved for the treatment of adults with relapsed or refractory acute myeloid leukemia with a susceptible IDH1 mutation, as detected by a U.S. Food and Drug Administration (FDA)-approved test.1 The FDA simultaneously approved the Abbott...
MAGNOLIA Trial: Zanubrutinib Yields High Response Rates With Low Rate of Cardiac Events in Marginal Zone Lymphoma
Zanubrutinib—a next-generation Bruton’s tyrosine kinase (BTK) inhibitor—achieved high response rates and durable disease control with a low incidence of cardiac effects in patients with relapsed or refractory marginal zone lymphoma, according to updated findings from the final analysis of the phase ...
Subset of Patients With Advanced Gastric/GEJ Cancer May Benefit From CLDN18.2-Targeted Drug Zolbetuximab: SPOTLIGHT Study
Initial data from the global phase III SPOTLIGHT trial could herald the use of a new targeted agent for a subset of patients with advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma. First-line treatment with zolbetuximab, which targets the transmembrane protein claudin 18.2...
Is the Risk of Suicide Higher Among Individuals With Cancer?
According to a large new study led by researchers at the American Cancer Society, the risk of suicide for individuals diagnosed with cancer in the United States is 26% higher compared with the general population. Geographic, racial/ethnic, socioeconomic, and clinical characteristics contributed to...
Futibatinib in Previously Treated Patients With Advanced FGFR2-Rearranged Intrahepatic Cholangiocarcinoma
In a phase II study (FOENIX-CCA2) published in The New England Journal of Medicine, Lipika Goyal, MD, and colleagues found that the next-generation, covalently binding FGFR1-4 inhibitor futibatinib showed activity in previously treated patients with unresectable or metastatic FGFR2-altered...
Is Zanubrutinib Poised to Become a New Standard of Care in Relapsed or Refractory CLL and SLL?
The next-generation Bruton’s tyrosine kinase (BTK) inhibitor zanubrutinib demonstrated superior progression-free survival compared with ibrutinib, with an improved cardiac safety profile, in the first head-to-head comparison between these two BTK inhibitors in relapsed or refractory chronic...
Tremelimumab-actl in Combination With Durvalumab for Unresectable Hepatocellular Carcinoma
On October 21, 2022, tremelimu-mab-actl was approved by the U.S. Food and Drug Administration (FDA) for use in combination with durvalumab in the treatment of unresectable hepatocellular carcinoma.1 Supporting Efficacy Data Approval was based on a comparison of overall survival in the...
Expert Point of View: Mikkael Sekeres, MD
“Standard treatment of older or less fit adults with acute myeloid leukemia (AML) is now venetoclax/azacitidine, which has been shown to improve overall survival vs azacitidine monotherapy. Since that backbone was established, there has been a tsunami of trials looking at drugs added to this...
Studies Explore Novel Triplet Combinations in AML
Two separate studies presented at the 2022 American Society of Hematology (ASH) Annual Meeting and Exposition provide preliminary evidence that triplet combinations may have a role in the treatment of acute myeloid leukemia (AML). Both triplets were based on the addition of a third drug to standard ...
Study Finds Immune Checkpoint Inhibitors Safe and Effective for Patients Living With HIV Who Have NSCLC
Immune checkpoint inhibitors are safe and effective for people living with HIV who have metastatic non–small cell lung cancer (NSCLC), according to data presented at the 2022 Society for Immunotherapy of Cancer (SITC) Annual Meeting.1 Findings from the first matched cohort to compare clinical...
Expert Point of View: Ajay K. Nooka, MD, MPH
Insights on findings from the phase II MonumenTAL-1 trial1 were offered by Ajay K. Nooka, MD, MPH, Professor in the Department of Hematology and Medical Oncology, and Medical Director of the Winship Data and Technology Applications Shared Resource, Winship Cancer Institute, Emory University School ...
Palbociclib/Fulvestrant Does Not Improve Progression-Free Survival After Progression on a CDK4/6 Inhibitor in Metastatic Breast Cancer
The combination of palbociclib and fulvestrant did not prolong progression-free survival compared to fulvestrant alone in patients with hormone receptor–positive/HER2-negative metastatic breast cancer who had disease progression on prior treatment with a CDK4/6 inhibitor and endocrine therapy,...
Study Shows Activity of Talquetamab in Highly Refractory Multiple Myeloma
In the phase I/II MonumenTAL-1 trial, the novel bispecific antibody talquetamab produced responses in more than 70% of heavily pretreated patients with multiple myeloma.1 Of note, the safety profile confirmed results of the phase I portion of the study (recently published in TheNew England Journal...
Neoadjuvant Gemcitabine/Cisplatin in High-Risk Upper Tract Urothelial Carcinoma
In a phase II trial reported in the Journal of Clinical Oncology, Coleman et al found that neoadjuvant split-dose gemcitabine and cisplatin produced a high rate of pathologic response in patients with high-risk localized upper tract urothelial carcinoma. The investigators also showed that...
Study Suggests Ibrutinib May Obviate Need for Autologous Stem Cell Transplantation in Some Younger Patients With Mantle Cell Lymphoma
Although longer follow-up is needed, the results of the three-arm randomized TRIANGLE study suggest that the tyrosine kinase inhibitor ibrutinib may replace autologous stem cell transplantation (ASCT) after chemoimmunotherapy in younger patients with previously untreated mantle cell lymphoma (MCL). ...
Study Suggests Ibrutinib May Obviate Need for ASCT in Some Younger Patients With Mantle Cell Lymphoma
Although longer follow-up is needed, the results of the three-arm randomized TRIANGLE study suggest that the tyrosine kinase inhibitor ibrutinib may replace autologous stem cell transplantation (ASCT) after chemoimmunotherapy in younger patients with previously untreated mantle cell lymphoma (MCL). ...
Carfilzomib, Lenalidomide, and Dexamethasone vs Lenalidomide in Maintenance Therapy After ASCT in Newly Diagnosed Multiple Myeloma
As reported in The Lancet Oncology by Dominik Dytfeld, MD, PhD, and colleagues, an unplanned interim analysis of the phase III ATLAS trial has shown improved progression-free survival with carfilzomib, lenalidomide, and dexamethasone (KRd) vs lenalidomide alone as maintenance after autologous stem...
Frequency and Dosage of Radiotherapy in Chemoradiotherapy for Limited-Stage SCLC
As reported in the Journal of Clinical Oncology by Jeffrey Bogart, MD, and colleagues, the phase III CALGB 30610/RTOG 0538 trial has shown no significant difference in overall survival with 70-Gy once-daily vs 45-Gy twice-daily radiotherapy in a chemoradiotherapy regimen for limited-stage small...
Blinatumomab Improves Survival in MRD-Negative, B-Cell ALL
The standard of care could be changing for adults with newly diagnosed BCR-ABL–negative B-lineage acute lymphoblastic leukemia (ALL) who achieve measurable residual disease (MRD) negativity after induction chemotherapy. In the phase III E1910 trial by the ECOG-ACRIN Cancer Research Group, an...
Subcutaneous Epcoritamab for Relapsed or Refractory Large B-Cell Lymphoma
As reported in the Journal of Clinical Oncology by Catherine Thieblemont, MD, PhD, and colleagues, findings in a dose-expansion cohort of the phase I/II EPCORE NHL-1 study indicated high activity of the subcutaneous CD3 x CD20 T-cell–engaging bispecific antibody epcoritamab in patients with...
Novel Therapy Afamitresgene Autoleucel Shows Early Potential for Antitumor Activity
The adoptive T-cell receptor therapy afamitresgene autoleucel—which targets the MAGE-A4 cancer antigen—achieved clinically significant results for patients with multiple solid tumor types in a phase I clinical trial, according to a novel study published by Hong et al in Nature Medicine. Initial...
Sotorasib in Previously Treated Patients With KRAS G12C–Mutated Advanced Pancreatic Cancer
In the phase I/II CodeBreaK 100 trial reported in The New England Journal of Medicine, John H. Strickler, MD, and colleagues found that the KRAS G12C inhibitor sotorasib showed activity in previously treated patients with advanced pancreatic cancer and a KRAS G12C mutation. Study Details In the...
POLLUX Trial Final Overall Survival Analysis: Addition of Daratumumab to Lenalidomide/Dexamethasone in Previously Treated Patients With Multiple Myeloma
As reported in the Journal of Clinical Oncology by Meletios A. Dimopoulos, MD, and colleagues, the final overall survival analysis of the pivotal phase III POLLUX trial has shown a significant benefit with the addition of daratumumab to lenalidomide and dexamethasone after a median follow-up of...
Adagrasib With or Without Cetuximab in Previously Treated Patients With Metastatic Colorectal Cancer and a KRAS G12C Mutation
In the phase I/II KRYSTAL-1 trial reported in The New England Journal of Medicine, Rona Yaeger, MD, and colleagues found that the KRAS G12C inhibitor adagrasib showed activity alone and in combination with cetuximab in heavily pretreated patients with metastatic colorectal cancer and mutated KRAS...
KEYNOTE-394: Pembrolizumab as Second-Line Therapy in Asian Patients With Advanced HCC
As reported in the Journal of Clinical Oncology by Qin et al, the phase III KEYNOTE-394 trial showed overall and progression-free survival benefits with pembrolizumab vs placebo in previously treated Asian patients with advanced hepatocellular carcinoma (HCC). Study Details The double-blind trial...
Addition of Adjuvant Nab-paclitaxel to Gemcitabine in Pancreatic Ductal Adenocarcinoma
As reported in the Journal of Clinical Oncology by Margaret A. Tempero, MD, and colleagues, the phase III APACT trial has shown no improvement in independently assessed disease-free survival (the study’s primary endpoint) with the addition of adjuvant nab-paclitaxel to gemcitabine in...
Endoscopic Surveillance With Systematic Random Biopsy vs Targeted Biopsy for Early Diagnosis of Hereditary Diffuse Gastric Cancer
In a UK study reported in The Lancet Oncology, Lee et al found that systematic random biopsies were more likely than endoscopically targeted biopsies to first detect signet ring cell carcinoma during endoscopic surveillance of individuals meeting testing criteria for hereditary diffuse gastric...
World Cancer Day 2023: February 4
World Cancer Day 2023 is now only 1 month away! Led by the Union for International Cancer Control (UICC) and organized annually on February 4, World Cancer Day is a global initiative to improve awareness and knowledge of cancer risks and better prevent, detect, and treat the disease. World Cancer...
Triple Immunotherapy Combination Studied Preclinically for Pancreatic Cancer
Researchers at The University of Texas MD Anderson Cancer Center have discovered a novel immunotherapy combination, targeting checkpoints in both T cells and myeloid suppressor cells, that successfully reprogrammed the tumor immune microenvironment and significantly improved antitumor responses in...
Nearly All Oncology Providers Report Prior Authorization Causing Delayed Care, Other Patient Harms
Prior authorization is harming individuals with cancer, according to new survey results from ASCO. The survey found that prior authorization delays necessary care, worsens cancer care outcomes, and diverts clinicians from caring for their patients. Nearly all survey participants reported a patient...
Mirvetuximab Soravtansine for FRɑ-Positive, Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer
On November 14, 2022, the U.S. Food and Drug Administration (FDA) granted mirvetuximab soravtansine-gynx accelerated approval for patients with folate receptor alpha (FRα)-positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received one to three...
Barbara Burtness, MD, Named Chief Translational Research Officer for Yale Cancer Center and Smilow Cancer Hospital
Barbara Burtness, MD, Professor of Medicine (Medical Oncology), has been named Chief Translational Research Officer for Yale Cancer Center and Smilow Cancer Hospital and Associate Cancer Center Director for Translational Research for Yale Cancer Center. Dr. Burtness’ experience, leadership, and...
A Lifelong Love of Science Leads to a Leadership Role in Oncology for Laurie Glimcher, MD
For this installment of The ASCO Post’s Living a Full Life series, Guest Editor Jame Abraham, MD, FACP, spoke with Laurie Glimcher, MD, President and Chief Executive Officer (CEO) of Dana-Farber Cancer Institute (DFCI). She is also Director of the Dana-Farber/Harvard Cancer Center, Principal...
From the Clinic to the Lab: Overcoming Resistance to Immune Checkpoint Therapy
As a result of breakthroughs in immune checkpoint inhibitors over the past decade, immunotherapy has joined surgery, radiation therapy, and chemotherapy as one of the pillars of cancer treatment. However, nearly half of patients still do not benefit from immune checkpoint blockade. During the 2022...
How the American Cancer Society Aims to Improve Outcomes in Breast and Cervical Cancers and Reduce Health Disparities
Just days before the publication of the 2022 Annual Report to the Nation on the Status of Cancer on October 27, 2022,1 which showed a continued downward trend in cancer deaths, Karen Knudsen, MBA, PhD, Chief Executive Officer of the American Cancer Society (ACS), joined the First Lady Dr. Jill...
Ribociclib Plus Endocrine Therapy vs Combination Chemotherapy for Patients With Breast Cancer: Focus on Those in Visceral Crisis
According to findings from the phase II RIGHT Choice trial, many premenopausal patients with metastatic hormone receptor–positive, HER2-negative breast cancer experiencing visceral crisis are best treated with first-line ribociclib plus endocrine therapy rather than with chemotherapy.1 Ribociclib,...
Nivolumab Plus Cabozantinib With or Without Ipilimumab in Advanced Hepatocellular Carcinoma
As reported in the Journal of Clinical Oncology by Thomas Yau, MD, and colleagues, findings in a cohort of the phase I/II CheckMate 040 trial indicated the activity of nivolumab/cabozantinib with or without ipilimumab in patients with advanced hepatocellular carcinoma. Study Details In the...
Cedars-Sinai Cancer Leaders Assume New Roles
Lali Medina-Kauwe, PhD, former Co-Leader of the Cancer Biology Program in Cedars-Sinai Cancer, assumed a new role as Associate Director for Basic Research. The Cancer Biology Program will now be led by Dolores Di Vizio, MD, PhD, Professor of Biomedical Sciences, Pathology and Laboratory Medicine in ...
Fox Chase Receives $6 Million Grant as Founding Member of New NCI Prevention Initiative
Fox Chase Cancer Center was recently awarded a grant for $6 million over the course of 5 years to develop a new Cancer Prevention-Interception Targeted Agent Discovery Program (CAP-IT). The new National Cancer Institute (NCI) program was created to establish a pipeline for the discovery of new...
FDA Approves Pafolacianine to Aid Lung Cancer Surgery
The U.S. Food and Drug Administration (FDA) has approved the targeted imaging agent pafolacianine (Cytalux) for use in lung cancer surgery. This injectable diagnostic binds to cancerous tissue and glows when stimulated by near-infrared light, making it easier for surgeons to remove tumors...
Sidney Kimmel Cancer Center Establishes Geriatric Oncology Center of Excellence at Jefferson Health
Jefferson Health’s Sidney Kimmel Cancer Center (SKCC) recently launched the Geriatric Oncology Center of Excellence to address the needs of a growing patient population through innovative research and care delivery methods via a multidisciplinary approach. The center identifies and removes barriers ...
From Immigrant Roots to a Budding Career in Oncology, Gladys Magaly Rodriguez, MD, Aims to Advance Health Equity in Vulnerable Populations
Gladys Magaly Rodriguez, MD, was born in Piedras Negras, Mexico, a city situated along the banks of the Rio Grande. At age 6, her family immigrated to Eagle Pass, Texas, a border town of some 30,000 people that is predominantly Latinx and Spanish speaking. “Even though I lived and attended school...
Tremelimumab Combined With Durvalumab and Platinum-Based Chemotherapy in Metastatic NSCLC
On November 10, 2022, tremelimu-mab in combination with durvalumab and platinum-based chemotherapy was approved for patients with metastatic non–small cell lung cancer (NSCLC) with no sensitizing EGFR mutation or ALK genomic tumor aberrations.1 Supporting Efficacy Data Approval was supported by...
Alex Herrera, MD, Finds a Path From the Baseball Fields of Miami to a Leadership Role at City of Hope
Lymphoma expert Alex Herrera, MD, was born in Miami; his parents were just 19 years old when he was born. Dr. Herrera’s father was born in Puerto Rico to Cuban and Ecuadorian parents. His mother was born in Cuba and came to the United States via Operation Peter Pan, the clandestine program that...
Adavosertib in Refractory Solid Tumors With CCNE1 Amplification
In a phase II trial reported in the Journal of Clinical Oncology, Fu et al found that the WEE1 kinase inhibitor adavosertib was active in patients with refractory solid tumors with CCNE1 amplification, with evidence of increased activity in epithelial ovarian cancer. Study Details In the trial, 30...
TIL Therapy vs Ipilimumab in Advanced Melanoma
In a Dutch-Danish phase III trial reported in The New England Journal of Medicine, Rohaan et al found that tumor-infiltrating lymphocyte (TIL) therapy prolonged progression-free survival vs ipilimumab in patients with advanced melanoma. Study Details The open-label trial included 168 patients...
Scientists Map Genetic Evolution of CLL to Richter Syndrome
Richter syndrome is an aggressive lymphoma that develops in up to 1% of patients with chronic lymphocytic leukemia (CLL) and it serves as an example of histologic transformation. While recent advances have transformed the treatment landscape of CLL, Richter syndrome remains associated with poor...
Zanubrutinib Found Superior to Ibrutinib for CLL and SLL
Zanubrutinib showed superior efficacy to ibrutinib—with fewer side effects—in the first head-to-head comparison between the Bruton’s tyrosine kinase (BTK) inhibitors among patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL), according to data presented by Jennifer...
Simplified Treatment Regimen Reduces Early Deaths in Patients With APL
The use of a simplified treatment regimen by oncologists—along with management recommendations and 24/7 support provided by a limited and dedicated group of academic disease experts—resulted in a decrease in early deaths from acute promyelocytic leukemia (APL). In the multicenter prospective trial...
Pilot Study Investigates Axicabtagene Ciloleucel in Primary and Secondary CNS Lymphoma
The chimeric antigen receptor (CAR) T-cell therapy axicabtagene ciloleucel was deemed safe and showed encouraging signs of efficacy in a small pilot trial involving patients with lymphoma of the brain and/or spinal cord, according to findings presented by Caron A. Jacobson, MD, MMSc, and colleagues ...
